Login to Your Account



CMS Panel Urges Cautious Use of ESAs in Predialysis Patients

By Donna Young


Friday, March 26, 2010
WASHINGTON - A Medicare advisory panel Wednesday said evidence backed the use of Amgen Inc.'s Epogen (epoetin alfa) and Aranesp (darbepoetin alfa) and Centocor Ortho Biotech Products LP's Procrit (epoetin alfa) as therapies to manage anemia in dialysis patients with chronic end-stage renal disease (ESRD). (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription